Mediators of Inflammation / 2013 / Article / Fig 2

Research Article

Dose-Dependent Anti-Inflammatory and Neuroprotective Effects of an ανβ3 Integrin-Binding Peptide

Figure 2

((a)–(g)) C16 treatment attenuated the CD4+ lymphocytes extravasation in CNS both at weeks 2 and 8 after immunization. CD4 immunostaining, counterstained with hematoxylin; bar = 100 μm. At week 2 after immunization, normal group (a), vehicle control rats (b) (with severe cellular infiltration within parenchyma and surrounding blood vessel), 1 mg /day C16 treated EAE rats (c), C16 late treated EAE rats (d) (the arrow denotes “perivascular cuffing” of CD4+ lymphocyte). At week 8 after immunization, vehicle control rats (e), and 1 mg/per day C16 treated EAE rats (f), and C16 late treated EAE rats (g). ((h)–(j)) The C16 treatment attenuated the leukocytes infiltration in CNS both at weeks 2 and 8 after immunization. TRITC conjugated CD45 immunofluorescent staining. At week 2 after immunization, vehicle control rats (h), 2 mg/per day C16 treated EAE rats (i), and C16 late treated EAE rats (j). ((k)–(p)) The C16 treatment attenuated macrophages extravasation in CNS both at weeks 2 and 8 after immunization. TRITC conjugated CD68 immunofluorescent staining. At week 2 after immunization, vehicle control rats (k), 2 mg/per day C16 treated EAE rats (l), and C16 late treated EAE rats (m). At week 8 after immunization, vehicle control rats (n), 2 mg/day C16 treated EAE rats (o), and C16 late treated EAE rats (p).
268486.fig.002a
(a)
268486.fig.002b
(b)
268486.fig.002c
(c)
268486.fig.002d
(d)
268486.fig.002e
(e)
268486.fig.002f
(f)
268486.fig.002g
(g)
268486.fig.002h
(h)
268486.fig.002i
(i)
268486.fig.002j
(j)
268486.fig.002k
(k)
268486.fig.002l
(l)
268486.fig.002m
(m)
268486.fig.002n
(n)
268486.fig.002o
(o)
268486.fig.002p
(p)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.